Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birabresib in recurrent glioblastoma multiforme
NCT02296476Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of birabresib in glioblastoma multiforme (GBM), sponsored by Merck & Co.. Started Oct 2014; status: terminated.
02
Drugs
birabresib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02296476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296476.